All 1 tracked stories fall under one category: markets. Broadcom is the most frequent co-covered peer, appearing in 1 of the 1 tracked story. At 5, the average consequence score sits below the same-window beat average of 6.4. Each story carries 2 original sources on average, compared with 2.7 for the broader beat in this window.
Figures are computed live from our source-verified story record
— see our methodology for how impact and
sentiment are derived.
What the coverage shows about Rocket Pharmaceuticals
All 1 tracked stories fall under one category: markets. Broadcom is the most frequent co-covered peer, appearing in 1 of the 1 tracked story. At 5, the average consequence score sits below the same-window beat average of 6.4. Each story carries 2 original sources on average, compared with 2.7 for the broader beat in this window. We currently track 1 Finance story that mention Rocket Pharmaceuticals, all published on March 19, 2026.
Stories tracked
1
Sources per story
2
Computed from the 1 stories linked to this entity, with beat comparisons drawn from all 105 Finance stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Appears alongside
Other entities that clear the same relevance threshold in stories also covering Rocket Pharmaceuticals. Shared-story counts are live from our verified record — not editorial picks.
Rocket Pharmaceuticals (RCKT) shares fell 4.4% following recent clinical and financial updates, while Broadcom (AVGO) slipped 1.1% as the company faces a new EU antitrust complaint regarding its VMware acquisition.
Rocket Pharmaceuticals is linked from 1 story on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source
link? Report a data issue.